L’Oreal Sunscreen TEA Falls Short On Safety, Efficacy, AE Data
This article was originally published in The Rose Sheet
Executive Summary
Ahead of NDAC’s discussion of tests for evaluating the safety of sunscreen ingredients, FDA issues its fourth letter this year to sunscreen TEA applicants citing insufficient data. FDA says it needs additional data on safety, efficacy and adverse events from L’Oreal to determine GRASE for drometrizole trisiloxane, marketed as Mexoryl XL.
You may also be interested in...
All OTC Ingredient TEAs Get Review Deadlines In Senate Draft Bill
Senate HELP committee leaders release a draft bill for discussion that builds on the Sunscreen Innovation Act and its proposed deadlines for FDA review of sunscreen TEA applications, adding provisions that would require FDA to set “reasonable” review deadlines for all OTC ingredient TEAs.
FDA Proposal For Increased Sunscreen Safety Testing On NDAC Agenda
FDA’s Nonprescription Drug Advisory Committee will consider proposed tests for evaluating the safety of sunscreen ingredients that sponsors want to add to the OTC monograph. The committee will not consider the safety or efficacy of specific ingredients pending review via TEAs.
FDA Faults BASF Sunscreen Ingredient Data In Latest TEA Rejection
FDA advises BASF that the information the firm submitted is not sufficient to establish octyl triazone as GRASE. The agency’s third rejection this year of a sunscreen time-and-extent application could raise concerns among lawmakers and industry members amid a push to move sunscreen ingredients through the TEA process so consumers have access to updated options for sun protection.